Share on StockTwits

Shares of Hologic (NASDAQ:HOLX) have been given a consensus rating of “Hold” by the twenty-one analysts that are covering the company, American Banking News reports. Two research analysts have rated the stock with a sell recommendation, ten have given a hold recommendation and five have given a buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $23.83.

Shares of Hologic (NASDAQ:HOLX) traded down 0.59% on Thursday, hitting $25.45. 154,741 shares of the company’s stock traded hands. Hologic has a 52 week low of $18.46 and a 52 week high of $26.18. The stock’s 50-day moving average is $24.5 and its 200-day moving average is $22.39. The company’s market cap is $7.032 billion.

Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, April 30th. The company reported $0.37 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.33 by $0.04. The company had revenue of $625.00 million for the quarter, compared to the consensus estimate of $609.35 million. On average, analysts predict that Hologic will post $1.40 earnings per share for the current fiscal year.

A number of research firms have recently commented on HOLX. Analysts at Zacks reiterated a “neutral” rating on shares of Hologic in a research note on Wednesday. They now have a $26.00 price target on the stock. Separately, analysts at Needham & Company LLC raised their price target on shares of Hologic from $26.00 to $30.00 in a research note on Wednesday. They now have a “buy” rating on the stock. Finally, analysts at Argus raised their price target on shares of Hologic from $27.00 to $31.00 in a research note on Monday, May 12th. They now have a “buy” rating on the stock.

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products to serving the healthcare needs of women.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.